| 生物活性 |
Pongamol (Lanceolatin C) is an orally active flavonoid that inhibits PTPase-1B with an IC50 of 75 μM and a Ki of 58 μM and intestinal α-Glycosidase with an IC50 of 103.5 μM, reduces the release of IL‑1β, TNF‑α, COX‑2, and iNOS in cells, reverses NF‑κB nuclear translocation, upregulates Beclin 1 and LC3 Ⅱ/LC3 Ⅰ levels, promotes glucose uptake by increasing GLUT4 levels on the surface of skeletal muscle cells, inhibits epithelial-mesenchymal transition by suppressing the FAK/Akt-mTOR signaling pathway, inhibits neurotoxicity in neuronal cells, suppresses apoptosis (Apoptosis), and extends the lifespan of Caenorhabditis elegans by activating the MAPKs/Nrf2 signaling pathway, exhibits antibacterial activity, exerts hypoglycemic effects in diabetic mouse models, and in Alzheimer's disease mouse models attenuates oxidative stress, neuroinflammation, Aβ deposition, and Tau protein (Tau Protein) hyperphosphorylation and restores autophagy (Autophagy) function by inhibiting the Akt/mTOR signaling pathway, and can be used for research related to Alzheimer's disease, type 2 diabetes, non-small cell lung cancer, and postprandial hyperglycemia. |
体外研究 (In Vitro) |
Pongamol (25-100 μM, 预孵育 1 h,随后 LPS 刺激 24 h) 抑制 BV2 小鼠小胶质细胞中 LPS (MS-X54539) 诱导的 NO 释放,通过降低 IκB 磷酸化并阻断 NF-κB 核转位,抑制 细胞中 LPS 诱导的 NF-κB 通路激活,下调细胞中促炎基因 (IL-1β、TNF-α、iNOS、COX-2) 的表达。 Pongamol (100 μM, 预处理 1 h,随后给予 LPS 刺激 24 h) 可降低 LPS 刺激的 BV2 小鼠小胶质细胞中促炎蛋白 (IL-6、IL-1β) 的水平,并上调自噬标志物 (Beclin 1、LC3 II/LC3 I) 的表达,且这些效应依赖于 Akt 通路。 Pongamol (0-10 μM; 0-16 h) 增加 L6-GLUT4myc 肌管细胞的基础及胰岛素叠加型葡萄糖摄取,通过激活 PI3-激酶活性提升细胞表面的基础型及胰岛素增强型 GLUT4 转位,增强肌管中 Insulin (MS-R27415) 诱导的 AKT (Ser-473) 磷酸化。 Pongamol (0-100 μM, 2 h) 提升经 H2O2 诱导的 PC12 细胞存活率,降低细胞中 LDH 的释放,抑制细胞凋亡,恢复线粒体膜电位,降低促凋亡蛋白水平并提高抗凋亡蛋白水平,抑制细胞中 MAPKs 信号通路激活 (降低 p-ERK、p-JNK 及 p-p38 水平),提升 GSH 水平降低 ROS 水平,促进 Nrf2 核转位、上调下游抗氧化基因表达及直接结合 Keap1,激活 Nrf2/HO-1 信号通路。 Pongamol (0-100 μM; 24-48 h) 可呈剂量依赖性降低 H460 非小细胞肺癌细胞的存活率,抑制细胞的增殖、锚定非依赖性生长、迁移、侵袭能力。 Pongamol (25-100 μM; 24 h) 在 H460 非小细胞肺癌细胞中上调上皮标志物 E-cadherin,下调间质标志物 N-cadherin、波形蛋白 (vimentin)、Slug 和 Snail,抑制 细胞中 FAK/Akt-mTOR 信号通路的激活,降低磷酸化 FAK、Akt 和 mTOR 的水平。 Pongamol (Compound 1) 在无细胞实验中抑制重组蛋白酪氨酸磷酸酶-1B (PTPase-1B),其 IC50 为 75 μM,Ki 为 58 μM。 Pongamol (Compound 6) 可强效抑制大鼠肠道 α-葡萄糖苷酶,其 IC50 为 103.5 μM。 Pongamol 对大肠杆菌和金黄色葡萄球菌具有活性 (MIC 分别为 8 和 6 µg/mL)。
Western Blot Analysis
| Cell Line: |
LPS-stimulated BV2 mouse microglia |
| Concentration: |
25, 50, 100 μM |
| Incubation Time: |
1 h pre-incubation, followed by 24 h LPS stimulation |
| Result: |
Dose-dependently decreased the p-IκB/IκB ratio in cytoplasmic fractions and significantly inhibited the nuclear translocation of p-NF-κB/NF-κB relative to the LPS-only model group. |
Real Time qPCR
| Cell Line: |
LPS-stimulated BV2 mouse microglia |
| Concentration: |
25, 50, 100 μM |
| Incubation Time: |
1 h pre-incubation, followed by 4 h LPS stimulation |
| Result: |
Dose-dependently reduced the mRNA expression levels of IL-1β, TNF-α, iNOS, and COX-2 relative to the LPS-only model group. |
Western Blot Analysis
| Cell Line: |
LPS-stimulated BV2 mouse microglia |
| Concentration: |
100 μM |
| Incubation Time: |
1 h pre-incubation, followed by 24 h LPS stimulation |
| Result: |
Significantly decreased IL-6 and IL-1β protein expression, and increased Beclin 1 and LC3 II/LC3 I protein levels relative to the LPS-only model group; these effects were reversed by co-treatment with wortmannin. |
Western Blot Analysis
| Cell Line: |
Differentiated L6-GLUT4myc skeletal muscle myotubes |
| Concentration: |
10 μM |
| Incubation Time: |
16 h |
| Result: |
Significantly potentiated insulin-stimulated AKT (Ser-473) phosphorylation to 7.8-fold of control basal. |
Cell Viability Assay
| Cell Line: |
Highly differentiated PC12 cells |
| Concentration: |
5-100 μM (5-80 μM for H2O2 co-treatment; 5, 10, 20, 40, 60, 80, and 100 μM pongamol) |
| Incubation Time: |
2 h pretreatment, followed by 24 h H2O2 co-treatment; duration of assay (for pongamol alone testing) |
| Result: |
Exhibited no significant effect on PC12 cell survival when used alone. Increased cell survival in a concentration-dependent manner, with survival rates increased by 17.16%, 29.63%, and 44.29% at 20, 40, and 80 μM, respectively, when used to pretreat cells before H2O2 exposure. |
Cell Cytotoxicity Assay
| Cell Line: |
Highly differentiated PC12 cells |
| Concentration: |
20, 40, and 80 μM |
| Incubation Time: |
2 h pretreatment, followed by 24 h H2O2 co-treatment |
| Result: |
Significantly reduced LDH release in a dose-dependent manner, with reductions of 33.16%, 50.59%, and 109.84% at 20, 40, and 80 μM, respectively, compared to H2O2-only treated cells. |
Apoptosis Analysis
| Cell Line: |
Highly differentiated PC12 cells |
| Concentration: |
20, 40, and 80 μM |
| Incubation Time: |
2 h pretreatment, followed by 24 h H2O2 co-treatment |
| Result: |
Reduced the proportion of early and late apoptotic cells in a concentration-dependent manner; at 80 μM, the total apoptotic rate was reduced to 7.04%, compared to 39.57% in H2O2-only treated cells. |
Western Blot Analysis
| Cell Line: |
Highly differentiated PC12 cells |
| Concentration: |
20, 40, and 80 μM |
| Incubation Time: |
2 h pretreatment, followed by 24 h H2O2 co-treatment |
| Result: |
Prevented the H2O2-induced increase in pro-apoptotic proteins Bax, Cyto C, Cleaved Caspase-3, and Cleaved PARP1, and prevented the H2O2-induced decrease in anti-apoptotic protein Bcl-2, resulting in a reduced Bax/Bcl-2 ratio. |
Western Blot Analysis
| Cell Line: |
Highly differentiated PC12 cells |
| Concentration: |
80 μM |
| Incubation Time: |
2 h pretreatment, followed by 1, 2, or 4 h H2O2 co-treatment; 2 h pretreatment, after MAPKs inhibitor pretreatment, followed by 24 h H2O2 co-treatment |
| Result: |
Reduced the H2O2-induced phosphorylation of ERK, JNK, and p38. Inhibitors of MAPKs pathways attenuated the effect of pongamol on reducing the Bax/Bcl-2 ratio in H2O2-treated cells. |
Cell Viability Assay
| Cell Line: |
H460 non-small cell lung cancer cells |
| Concentration: |
0, 10, 25, 50, 100 μM |
| Incubation Time: |
24 h |
| Result: |
Reduced cell viability in a dose-dependent manner. |
Cell Proliferation Assay
| Cell Line: |
H460 non-small cell lung cancer cells |
| Concentration: |
25, 50, 100 μM |
| Incubation Time: |
24 h, 48 h |
| Result: |
Significantly suppressed cell proliferation at 48 h compared to control. Significantly reduced proliferation at 50 and 100 μM compared to control. |
Cell Migration Assay
| Cell Line: |
H460 non-small cell lung cancer cells |
| Concentration: |
25, 50, 100 μM | ...(内容过长已截断)
体内研究 (In Vivo) |
Pongamol (10-20 mg/kg;i.g.;每日;4 周) 可通过抑制 Akt/mTOR 信号通路,改善 D-gal/NaNO2/AlCl3 诱导的阿尔茨海默病小鼠的空间学习记忆能力,减轻氧化应激、神经炎症、Aβ 沉积及 Tau 蛋白过度磷酸化,并恢复自噬功能。 Pongamol (15-60 μM;in NGM medium;从 L1 期至成虫期/L4 期给药处理 1-5 天) 可提高表达人类 Tau 蛋白的 BR5270 秀丽隐杆线虫阿尔茨海默病模型的头部摆动活性,提示其神经元功能得到改善,增强 DA2123 秀丽隐杆线虫自噬报告模型的自噬活性,降低了表达人源 Aβ/Tau 的阿尔茨海默病秀丽隐杆线虫模型中的脂褐素沉积水平与 Aβ mRNA 表达量。 Pongamol (50-100 mg/kg;i.g.;单次给药) 在 Streptozotocin (MS-Q80520) 诱导的糖尿病大鼠中可产生显著的剂量依赖性降血糖作用。 Pongamol (100 mg/kg;i.g.;每日;连续 10 天) 可在 2 型糖尿病 db/db 小鼠中产生显著且持久的降血糖作用。
| Animal Model: |
C57BL/6 (male) |
| Dosage: |
10 mg/kg; 20 mg/kg |
| Administration: |
i.g.; daily; 4 weeks |
| Result: |
Significantly reduced escape latency. Increased platform crossing frequency. Increased time/distance spent in the target quadrant in the Morris water maze test. Decreased hippocampal acetylcholinesterase (AChE) and malondialdehyde (MDA) levels. Increased serum superoxide dismutase (SOD) and catalase (CAT) levels. Alleviated neuronal disorganization and loss in the hippocampus and cortex. Reduced Nissl body loss. Increased tyrosine hydroxylase (TH)-positive cell counts in the hypothalamus. Reduced neuronal nuclei (NeuN) expression in the cortex and hippocampus. Reduced glial fibrillary acidic protein (GFAP) and β-amyloid (Aβ) positive cell counts in the cortex and hippocampus. Inhibited Tau hyperphosphorylation in hippocampal tissue. Downregulated mRNA expression of IL-1β, TNF-α, iNOS, and COX-2 in the hippocampus. Increased hippocampal Beclin 1 expression. Increased the LC3 II/LC3 I ratio. Reduced p62 mRNA expression. Increased Atg13 mRNA expression. Decreased phosphorylated Akt (p-Akt) and phosphorylated mTOR (p-mTOR) protein levels in the hippocampus. |
| Animal Model: |
BR5270 (human Tau-expressing AD model); DA2123 (GFP-labeled LGG-1/LC3 autophagy reporter); UM0001 (human Aβ1-42/Tau-expressing) |
| Dosage: |
15 μM; 30 μM; 60 μM |
| Administration: |
in NGM medium; from L1 stage through adulthood; 1-5 day treatment at L4 stage |
| Result: |
Significantly increased the number of head wiggles in BR5270 C. elegans in a dose-dependent manner. Significantly increased the number of LGG-1:GFP puncta in DA2123 C. elegans in a dose-dependent manner, indicating enhanced autophagic activity. Reduced lipofuscin deposition in UM0001 worms in a concentration-dependent manner, with the 60 μM dose producing the greatest reduction in fluorescence intensity per unit area relative to untreated worms. Reduced Aβ mRNA expression in UM0001 worms in a concentration-dependent manner, with the 60 μM dose producing the lowest Aβ transcript levels.
|
| Animal Model: |
UM0001 (human Aβ1-42/Tau-expressing) |
| Dosage: |
15 μM; 30 μM |
| Administration: |
NGM plate supplementation |
| Result: |
Increased mRNA expression of Skn-1 and its downstream antioxidant genes Sod-1, Gcs-1, and Gst-4 in UM0001 worms in a concentration-dependent manner. |
| Animal Model: |
Sprague Dawley (male, 7-8 weeks old, 160 g, streptozotocin-induced diabetic) |
| Dosage: |
50 mg/kg; 100 mg/kg |
| Administration: |
i.g.; single dose |
| Result: |
Reduced blood glucose by 12.8% at 6 hours post-administration. Reduced blood glucose by 22.0% at 6 hours post-administration. |
| Animal Model: |
db/db (12-18 weeks old, 40 g, genetically diabetic) |
| Dosage: |
100 mg/kg |
| Administration: |
i.g.; daily; 10 consecutive days |
| Result: |
Reduced blood glucose by 35.7% overall, with significant reductions observed on days 13-15 and days 17-19. Improved glucose tolerance by 18.61% compared to controls, with significantly lowered postprandial blood glucose levels at 30, 60, 90, and 120 minutes post-load. |
|
| 性状 |
固体 |
| 颜色 |
Off-white to light yellow |
| 分子量 |
294.30 |
| 分子式 |
C18H14O4 |
| CAS No. |
484-33-3 |
| 别名 |
Lanceolatin C |
| 体内实验配方 |
10% DMSO+90% Saline: < 5 mg/mL (16.99 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. ![]() 10% DMSO+90% Corn Oil: 1 mg/mL (3.4 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (16.99 mM), Solution. ![]() 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 |
| 储存方式 |
| Powder |
-20°C |
3 years |
|
4°C |
2 years |
| In solvent |
-80°C |
6 months |
|
-20°C |
1 month |
|
| 运输条件 |
Room temperature in continental US; may vary elsewhere. |
|
溶液配制表
|
DMSO 中的溶解度 : 50 mg/mL (169.89 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO) | 可选溶剂 | 浓度 | 1 mg | 5 mg | 10 mg | 25 mg |
|---|
| DMSO | 1 mM | 3.3979 mL | 16.9895 mL | 33.9789 mL | 84.9473 mL | | 5 mM | 0.6796 mL | 3.3979 mL | 6.7958 mL | 16.9895 mL | | 10 mM | 0.3398 mL | 1.6989 mL | 3.3979 mL | 8.4947 mL | | 15 mM | 0.2265 mL | 1.1326 mL | 2.2653 mL | 5.6632 mL | | 20 mM | 0.1699 mL | 0.8495 mL | 1.6989 mL | 4.2474 mL | | 25 mM | 0.1359 mL | 0.6796 mL | 1.3592 mL | 3.3979 mL | | 30 mM | 0.1133 mL | 0.5663 mL | 1.1326 mL | 2.8316 mL | | 40 mM | 0.0849 mL | 0.4247 mL | 0.8495 mL | 2.1237 mL | | 50 mM | 0.0680 mL | 0.3398 mL | 0.6796 mL | 1.6989 mL | | 60 mM | 0.0566 mL | 0.2832 mL | 0.5663 mL | 1.4158 mL | | 80 mM | 0.0425 mL | 0.2124 mL | 0.4247 mL | 1.0618 mL | | 100 mM | 0.0340 mL | 0.1699 mL | 0.3398 mL | 0.8495 mL |
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。
该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。
|
动物实验计算换算器
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。
-
客服
2851296953
18923798467
微信洽谈
|